SUSMED,INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 532 JPY | +2.90% |
|
-0.37% | -60.15% |
| 2023 | SUSMED,Inc.(TSE:4263) added to S&P Global BMI Index | CI |
| 2022 | Walgreens Boots Alliance, Inc. Joins Sustainable Medicines Partnership | CI |
| Sales 2024 * | 346M 2.2M | Sales 2025 * | 600M 3.81M | Capitalization | 8.9B 56.54M |
|---|---|---|---|---|---|
| Net income 2024 * | -457M -2.9M | Net income 2025 * | -390M -2.48M | EV / Sales 2024 * | 12.5 x |
| Net cash position 2024 * | 4.58B 29.06M | Net cash position 2025 * | 4.02B 25.52M | EV / Sales 2025 * | 8.14 x |
| P/E ratio 2024 * |
-19.4
x | P/E ratio 2025 * |
-22.7
x | Employees | 33 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 49.74% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.90% | ||
| 1 week | -0.37% | ||
| 1 month | -2.39% | ||
| 3 months | -5.84% | ||
| 6 months | -60.91% | ||
| Current year | -60.15% |
1 week
507.00
546.00
1 month
507.00589.00
Current year
504.001 399.00
1 year
504.001 823.00
3 years
504.002 500.00
5 years
504.002 500.00
10 years
504.002 500.00
| Managers | Title | Age | Since |
|---|---|---|---|
Taro Ueno
FOU | Founder | 43 | 15-07-30 |
| Chief Tech/Sci/R&D Officer | 40 | 17-10-31 | |
Yusuke Yajima
COO | Chief Operating Officer | 39 | 19-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kuniaki Kaga
BRD | Director/Board Member | 72 | 20-12-31 |
Yasuhiro Yamada
BRD | Director/Board Member | 61 | 22-08-31 |
Taro Ueno
FOU | Founder | 43 | 15-07-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 532 | +2.90% | 59,100 |
| 24-05-30 | 517 | -0.39% | 70,100 |
| 24-05-29 | 519 | -3.35% | 67,800 |
| 24-05-28 | 537 | +0.94% | 41,300 |
| 24-05-27 | 532 | -0.37% | 53,100 |
Delayed Quote Japan Exchange, May 31, 2024 at 02:00 am EDT
More quotes
Susmed Inc is a Japan-based company mainly engaged in the digital therapeutics (DTx) development business. The Company operates through two business segments. The DTx Product segment is engaged in the development of application software products for treating diseases such as insomnia, breast cancer, chronic kidney diseases and others. The DTx Platform segment is engaged in the provision of general-purpose clinical trial systems and machine learning automatic analysis systems, as well as the provision of DTx development support services using systems.
Sector
IT Services & Consulting
Calendar
2024-08-08
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -60.15% | 56.6M | |
| -19.53% | 177B | |
| -3.23% | 159B | |
| +2.05% | 153B | |
| +5.13% | 100B | |
| +9.84% | 81.11B | |
| +22.85% | 75.87B | |
| -8.81% | 69.81B | |
| -31.57% | 45.63B | |
| -9.69% | 42.96B |
- Stock Market
- Equities
- 4263 Stock
